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Psychotic Features as the First Manifestation of 
22q11.2 Deletion Syndrome 
The 22q11.2 deletion is a genetic disorder which is characterized by abnormalities in cardiac 
functioning, facial structure, neurobehavioral development, T cell functioning, and velopharyn-
geal insufficiencies. In the presented case study, 22q11.2 deletion was found in a patient who 
has psychotic symptoms only. A 25-year-old woman with a history of hypoparathyroidism and 
hypothyroidism presented with auditory hallucinations and persecutory delusions. After three 
months of treatment with antipsychotic medications, the patient was readmitted with generalized 
tonic-clonic seizures. The following week, the patient went into sepsis. A fluorescent in situ hy-
bridization (FISH) analysis revealed the presence of a 22q11.2 microdeletion. This case study 
suggests that psychotic symptoms can develop prior to the typical symptoms of a 22q11.2 de-
letion. As such, psychiatrists should test for genetic abnormalities in patients with schizophre-
nia when these patients present with seizures and immunodeficiencies. 
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Introduction
The 22q11.2 deletion, also called velocardiofacial syndrome, is a genetic disorder which ty-
pically involves cardiac anomalies, facial anomalies, learning difficulties, hypocalcemia, and 
T cell abnormalities. Additionally, patients with 22q11.2 deletions are at higher risk of devel-
oping psychiatric disorders than is the general population. One-third of all individuals with 
22q11.2 deletion syndrome develop schizophrenia-like psychotic disorders.1,2 However, it is 
uncommon for the psychotic symptoms to present as the initial manifestation of a 22q11.2 de-
letion. As such, genetic abnormalities are generally unsuspected among patients presenting wi-
th psychosis, but without velocardiofacial anomalies. A case report of a patient diagnosed wi-
th schizophrenia which was later confirmed to be the result of a 22q11.2 deletion is provided.
Case
A 25-year-old female patient was admitted to the psychiatric ward due to auditory halluci-
nations. Eight months prior to the patient’s admittance to the psychiatric ward, she experien-
ced intermittent auditory hallucinations in the form of her ex-boyfriend’s voice saying that he 
would kill her. During the month prior to her admittance to the psychiatric ward, the auditory 
hallucinations increased in severity and frequency, and the patient developed persecutory de-
lusions. Additionally, the patient came to believe that she had been raped by her boyfriend. 
The patient also quit her job and withdrew from all social relationships. 
The patient had no history or family history of psychiatric problems. The patient had been 
diagnosed with hypothyroidism and hypoparathyroidism at the age of ten and was being treat-
ed with synthyroid and alfacalcidol. The patient’s pediatric endocrinologist regularly assessed 
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her thyroid and parathyroid function. After graduating from 
college, the patient was successfully employed and was main-
taining social relationships. Two years prior to the patient’s ad-
mittance to the hospital, she broke up with her boyfriend. 
Upon admittance to the psychiatric ward, the patient was 
hospitalized for 20 days, during which she was treated with a 
daily dose of 8 mg of risperidone. During this hospitalization, 
the patient was diagnosed with schizophrenia. The patient re-
ported that she was no longer having auditory hallucinations 3 
weeks after her admission. A computerized tomography (CT) 
scan of the patient’s brain revealed an asymmetric calcification 
in the bilateral basal ganglia; however, the patient had no his-
tory of neurological disorders, including seizures. Additional-
ly, the patient complained of abdominal distension following 
discharge from the hospital. An abdominal CT scan revealed 
multiple mesenteric lymphadenopathy; however, the esopha-
gogastroduodenoscopy and colonoscopy results were normal. 
The patient underwent screening tests for autoimmune diseas-
es including antinuclear antibodies test, anti-deoxyribonucleic 
acid test, perinuclear anti-neutrophil cytoplasmic antibodies 
test, and a cytoplasmic anti-neutrophil cytoplasmic antibodies 
test, the results of which were all negative. Echocardiography 
and electrocardiography were also free of abnormalities. The 
patient’s internist recommended a biopsy for abdominal lym-
phadenopathy; however, the patient refused.
Two months following the patient’s initial discharge from 
the psychiatric ward, the patient was rehospitalized due to the 
experience of generalized tonic-clonic seizures. A serum che-
mistry analysis showed normal calcium levels, and a brain CT 
showed no interval changes compared with the previous scan. 
The anticonvulsant, lamotrigine, was prescribed, and quetiap-
ine was used in place of the risperidone following the confir-
mation of seizures with an electro-encephalogram. A week fol-
lowing the rehospitalization, the seizures had ceased; how-
ever, the patient developed a fever. The fever subsided after 
one week and then developed again, resulting in septic shock. 
No fever focus was found despite various examinations and 
tests. A T cell test was performed and revealed a decrease in the 
total T cell count and a deficiency in CD8 cells. A 22q11.2 mi-
crodeletion was confirmed by a fluorescent in situ hybridiza-
tion analysis (Figure 1). 
Discussion
In this patient, psychotic symptoms preceded the other sym-
ptoms of 22q11.2 deletion syndrome. Patients with 22q11.2 
deletion syndrome generally have recurrent infections, as well 
as endocrine and neuropsychiatric abnormalities.3 However, 
it is uncommon for psychotic features to be the first manifes-
tation of 22q11.2 microdeletion. Additionally, the patient’s his-
tory of hypoparathyroidism was not indicative of genetic ab-
normalities. Several studies have reported higher rates of psy-
chotic disorders among patients with a 22q11.2 deletion than 
in the general population.1,2 Psychotic symptoms typically be-
gin in late adolescence and adulthood. The prevalence rate for 
psychosis among individuals with the 22q11.2 deletion is ap-
proximately 30%,1,2,4 and schizophrenia has been described as 
a behavioral phenotype of a 22q11.2 deletion.5 However, pre-
valence of a 22q11.2 deletion among patients with schizophre-
nia is unclear. Some investigators6-8 have reported greater than 
2% prevalence for 22q11.2 deletions among patients with 
schizophrenia, while other investigators report a less than 1% 
prevalence rate.9-12 One study12 reported that no 22q11.2 dele-
tions were detected in the approximately 300 patients with sc-
hizophrenia who were screened for the study, and other studi-
es9,10 have reported that only one of approximately 300 pa-
tients showed a 22q11.2 deletion. 
The biological mechanisms which are responsible for the de-
velopment of psychotic features in patients with a 22q11.2 
deletion have not been fully investigated. Catechol-o-methyl-
transferase is a potential cause of psychotic symptoms,6 which 
was not replicated in the 22q11.2 deleted patients with schizo-
phrenia or in schizophrenic patients. The PRODH and GNB1L 
genes are other candidates which may be associated with the 
development of schizophrenia in patients with 22q11.2 dele-
tion syndrome.13
In the present case, the patient was diagnosed with schizo-
phrenia with well-controlled hypocalcemia. In spite of the pa-
tient’s history of hypoparathyroidism and abdominal lymph-
adenopathies, she did not have facial anomalies or cardiac mal-
formations. Additionally, the patient displayed appropriate le-
vels of social functioning prior to the onset of the psychotic 
symptoms. Additional clinical findings, including seizures, fre-
quent urinary tract infections, and recurrent septicemia, were 
inconsistent with a diagnosis of a 22q11.2 genetic abnormality.
It is difficult to determine whether the patient’s seizures 
were caused by risperidone. However, it is known that the pa-
tient’s first seizure occurred following treatment with antipsy-
chotic medication. It is also possible that the seizure was a ma-
nifestation of the 22q11.2 deletion syndrome. Several case 
Figure 1. Result of fluorescent in situ hybridization analysis using a 
HIRA probe (110 kb). Chromosome 22q13 was labeled in green as 
a control. An orange signal indicates a locus at 22q11.2. There’s 
only one orange signal. The absence of orange signal indicates of 
the deletion of the HIRA locus at 22q11.2. HIRA: histone cell cycle 
regulation defective homolog A. 
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reports have presented seizures as a manifestation of 22q11.2 
deletions.14,15 Additionally, it is known that antipsychotic me-
dications may lower the seizure threshold; however, the pos-
sibility of developing seizures associated with risperidone is 
relatively low.16,17 The patient also had calcifications in the 
basal ganglia, and, as such, the antipsychotic may have further 
decreased the seizure threshold. 
This case reveals that psychotic symptoms may serve as the 
initial manifestation of 22q11.2 deletion syndrome. It is uncom-
mon for a patient with a 22q11.2 deletion to show no velo-
cardiofacial anomalies, especially in Korea.18 As such, psychi-
atrists should test for genetic abnormalities among patients 
with schizophrenia when these patients also present with sei-
zures and immunodeficiencies.
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